About the format
Forty-five-minute panel discussions with one moderator and up to four speakers run in parallel tracks on both days, covering financing, dealmaking, clinical development, regulation, manufacturing and the technologies changing all of them.
Panel discussions are where the conference argues. A sponsor or partner sets the theme, brings a moderator and up to four speakers, and the audience gets to ask questions at the end. Topics in 2026 ranged from policy volatility in pharmaceutical investment to biosimilar commercialization, syndication in early-stage biotech and Swiss-China partnerships.
Panel hosts receive a banner template to introduce their panelists on the holding slide, and every panel discussion is listed with its speakers on the conference website and in the printed conference guide.

Why take part
Position your organization on the topic you want to be known for, in front of the whole ecosystem.
Enough voices for a real debate, short enough to keep the room.
The Swiss Biotech Day is an in-person event only; what is said in the room stays candid.
Last edition
Monday, 16:30
What's next in R&D, innovation and clinical development?
Citeline, a Norstella company
Monday, 14:30
From endpoints to execution: best practices panel
Clario
Monday, 14:30
Engineering longevity for the future of health
Deloitte
Monday, 14:30
Building sustainable Swiss–China partnerships
KPMG
Tuesday, 12:15
Syndication in early-stage biotech: chances and challenges
BiomedVC
Tuesday, 16:00
Building resilient, value-creating transactions in an unpredictable environment
Baker McKenzie
Panel discussion slots are limited to the number of parallel rooms. Early enquiries get first choice of day and time.
Program